The future of JAK inhibition in myelofibrosis and beyond

The identification of aberrant JAK–STAT signaling in patients with myeloproliferative neoplasms has served as the basis for the development of a new class of targeted agents. Ruxolitinib, the first-in-class oral small molecule JAK1/2 inhibitor, has demonstrated clinical efficacy and shown a potentia...
Ausführliche Beschreibung

Gespeichert in:
Autor*in:

Mascarenhas, John O. [verfasserIn]

Cross, Nicholas C.P.

Mesa, Ruben A.

Format:

E-Artikel

Sprache:

Englisch

Erschienen:

2014transfer abstract

Umfang:

8

Übergeordnetes Werk:

Enthalten in: A new approach to model asphaltene induced permeability damage with emphasis on pore blocking mechanism - Ghadimi, Marzieh ELSEVIER, 2019, Burlington, Mass

Übergeordnetes Werk:

volume:28 ; year:2014 ; number:5 ; pages:189-196 ; extent:8

Links:

Volltext

DOI / URN:

10.1016/j.blre.2014.06.002

Katalog-ID:

ELV022504206

Nicht das Richtige dabei?

Schreiben Sie uns!